About this Research Topic
The development of targeted pharmacotherapy for pituitary adenomas is challenging but worthwhile for improving patients’ quality of life (QOL). In spite of their benign nature, pituitary adenomas lead to increased mortality and impaired QOL mainly due to abnormal hormone secretion and their effects. Although surgical development has achieved better outcomes, the management of patients who have residual tumors, recurrent tumors, or who rejected to receive operations need other treatment options, including radiation or medical therapy. Additionally, the development of better medical drugs in the future will be necessary for treating these benign tumors with lifelong effects.
The dopamine D2 receptor and somatostatin receptors are the two main targets of medical therapy for pituitary adenomas. To develop better medical treatments, an understanding of the mechanism of drug resistance against current therapy is required. Recently, the pathogenesis of pituitary adenomas, including their genetic and epigenetic abnormalities, has been discovered using current comprehensive technology. These investigations are also the suitable for the development of novel targeted therapies.
In this Research Topic, we welcome original articles or review papers introducing resistance mechanisms of current targeted therapies, the pathogenesis of pituitary adenomas related to possible treatment targets, and data related to novel targeted therapies for pituitary adenomas.
Keywords: Pituitary adenomas, tumorigenesis, targeted therapy, gene mutations, epigenetic changes
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.